Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles Authors: Yu-Nan Man, Mao-Lin He Published: 2026 ABSTRACT AbstractSEC61G, the γ subunit of the Sec61 translocon, has long been regarded as a passenger co-amplification target of EGFR on chromosome 7p11.2. Recent studies have revealed its independent oncogenic functions across multiple cancers. This review proposes a mechanism-based classification of SEC61G oncogenic activities: (1) immune checkpoint regulation via canonical translocation; (2) aberrant calcium signaling; and (3) non-canonical mechanisms independent of channel functions. We further delineate the pan-cancer expression and CRISPR-Cas9 dependency landscape, highlighting a dual “high expression, high dependency” profile in cervical squamous cell carcinoma. We distinguish current pore-targeting Sec61 inhibitors from subunit-specific strategies and propose future directions including PROTAC degraders and PPI inhibitors. Our review identifies SEC61G as a pan‑cancer prognostic biomarker and immunotherapy response predictor, with mechanistic evidence supporting its driver roles in glioblastoma, non‑small cell lung cancer, and colorectal cancer, whereas associations in other cancers remain correlative and require further validation.Keywords: SEC61G, Sec61 channel, pan-cancer, oncogenic mechanism, prognostic biomarker Introduction The Sec61 channel constitutes the principal gateway for the translocation of nascent polypeptides across the endoplasmic reticulum (ER) membrane. Its functional status directly regulates the ER protein-folding load and determines the activation threshold of the unfolded protein response. 1 During tumorigenesis, oncogene-driven increases in protein synthesis impose sustained translocation demand on the Sec61 channel. Although adaptive upregulation of channel activity can mitigate short-term stress, chronic hyperactivation results in irreversible disruption of ER homeostasis, thereby promoting malignant phenotypes, including apoptosis resistance, metabolic reprogramming, enhanced invasion, and metastasis. 2-4 The Sec61 channel is a heterotrimeric complex composed of α (SEC61A1/A2), β (SEC61B), and γ (SEC61G). 5 SEC61A forms the central pore and contains 10 transmembrane helices, serving as the primary conduit for nascent polypeptides crossing the ER membrane. SEC61B is a single-pass transmembrane protein that contributes to channel assembly and stability. SEC61G, the smallest subunit, consists of 68 amino acids and a single transmembrane helix. It stabilizes the three-dimensional conformation of the channel through interactions with SEC61A and participates in regulating channel gating during protein translocation. 6 Functional integrity of the Sec61 channel requires coordinated assembly of all three subunits; disruption of any component significantly impairs protein translocation efficiency. 7 Moreover, studies have demonstrated that the Sec61 channel functions as a passive ER Ca²⁺ leakage pathway, contributing to calcium homeostasis between the ER and cytosol. 8-10 Because SEC61G primarily contributes to channel assembly and regulation rather than direct substrate recognition, its independent biological significance has been historically underappreciated. Rationale for focusing on SEC61G SEC61G has attracted increasing attention due to its genomic co-localization with one of the most extensively studied oncogenes, epidermal growth factor receptor (EGFR). Both reside on chromosome 7p11.2, a feature that results in frequent co-amplification of SEC61G in EGFR-amplified tumors. This “hitchhiking” effect provided an important clue to its oncogenic potential. 11 The oncogenic role of SEC61G was first identified in glioblastoma (GBM). Using digital karyotyping and single nucleotide polymorphism arrays, Lu et al. identified chromosome 7p11.2 as the most frequently amplified region in GBM, encompassing both EGFR and SEC61G (or SEC61γ). SEC61G was overexpressed in 77% of GBM clinical samples, and its knockdown inhibited tumor cell proliferation and induced apoptosis, indicating its essential role in GBM cell survival. 11 Subsequently, Liu et al. analyzed The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas datasets and demonstrated that high SEC61G expression is significantly associated with poor prognosis following temozolomide (TMZ) therapy and radiotherapy. 12 These findings established SEC61G as a potential oncogenic co-amplification target of EGFR. At the level of gene rearrangement, Servidei et al. identified SEC61G–EGFR chimeric mRNA in 1 of 16 pediatric infratentorial ependymoma samples (WHO grade III), indicating that SEC61G may also contribute to tumor progression via gene fusion. 13 In non-small cell lung cancer (NSCLC), Han et al. reported that the lncRNA LINC02418 upregulates SEC61G expression by competitively binding miR-4677-3p, thereby promoting tumor cell proliferation and invasion. 14 In hepatocellular carcinoma (HCC), Gao et al. demonstrated that SEC61G knockdown suppresses proliferation, induces apoptosis, and impairs migration and invasion, providing the first evidence of its independent oncogenic role beyond GBM. 15 Subsequent studies have confirmed the oncogenic functions of SEC61G across multiple malignancies, including head and neck squamous cell carcinoma (HNSCC), breast cancer, renal cancer, colorectal cancer (CRC), and cervical cancer. 16-20 Notably, its mechanisms of action are highly context-dependent. In some cancers, SEC61G regulates the membrane localization of immune checkpoint proteins through its canonical role in protein translocation, while in others, it modulates ubiquitin-mediated degradation, calcium signaling, and metabolic reprogramming via non-canonical pathways. 18 , 19 Furthermore, upregulated SEC61G expression is strongly associated with the establishment of an immunosuppressive tumor microenvironment and reduced responsiveness to immunotherapy. 16 , 20 Small-molecule inhibitors targeting the Sec61 channel have entered early-phase clinical trials. 21 However, most studies have focused on the overall structure and function of the Sec61 complex, and a systematic review of the independent role of SEC61G in cancer remains lacking. 22 This review therefore integrates current knowledge on the expression patterns, prognostic significance, oncogenic mechanisms, and immunomodulatory functions of SEC61G across cancers. In addition, a pan-cancer dependency landscape based on the Dependency Map database is incorporated to provide a comprehensive multi-omics framework supporting the clinical translation of SEC61G as both a prognostic biomarker and therapeutic target. Gene structure, expression profile, and biological functions of SEC61G Gene localization and protein structure The SEC61G gene is located on chromosome 7p11.2 (GeneCards Database: https://www.genecards.org/cgi-bin/carddisp.pl?gene=SEC61G), a genomic region that also harbors the EGFR gene. It comprises six exons, and its canonical transcript (NM_014302.4) encodes a 68-amino-acid single-pass transmembrane protein with an approximate molecular weight of 7.7 kDa, making it the smallest subunit of the Sec61 heterotrimer. According to the UniProt Database (https://www.uniprot.org/uniprotkb/P60059/entry), SEC61G contains a transmembrane helical domain spanning amino acid residues 33–61. Topological analysis from the Membranome Database (https://biomembhub.org/membranome/proteins/3635) further refines this region to residues 36–56. This helix divides the protein into two domains: an N-terminal cytosolic region (residues 1–32) and a short C-terminal luminal region (residues 62–68). As a core component of the Sec61 translocon, SEC61G assembles with SEC61A and SEC61B to form a stable heterotrimer that mediates co-translational translocation of nascent polypeptides into the ER lumen. The AlphaFold2-predicted monomeric structure of SEC61G (https://www.rcsb.org/structure/AF_AFP60059F1) exhibits high confidence (predicted local distance difference test score = 91.87) and closely matches experimentally determined cryo-electron (cryo-EM) microscopy structures of the human Sec61 complex. In 2025, Park and Wang deposited a high-resolution cryo-EM structure of the human Sec61 complex bound to the small-molecule inhibitor KZR-261 (PDB ID: 9D6L; https://www.rcsb.org/structure/9D6L), in which chain B corresponds to SEC61G. These structural data, which accompanied the preclinical characterization of KZR-261 by Lowe et al., provide a foundation for understanding the conformation and druggability of SEC61G within the Sec61 channel. 21 Tissue expression and subcellular localization RNA-seq data from the Genotype-Tissue Expression and Human Protein Atlas databases indicate that SEC61G is highly expressed in metabolically active and secretory tissues, including the thyroid, liver, pancreas, kidney, colon, and placenta, whereas lower expression levels are observed in skeletal muscle, heart, and brain. Subcellular localization analyzes from UniProt and Reactome (https://reactome.org/content/detail/R-HSA-265003) consistently indicate that SEC61G is primarily localized to the ER membrane. Membranome similarly classifies it as an ER membrane protein. In normal cells, SEC61G functions as an integral component of the Sec61 heterotrimer, cooperating with ribosomes to mediate transmembrane translocation of nascent polypeptides. Classical physiological functions Core function: co-translational protein translocation SEC61G is an essential component of the Sec61 translocon complex and participates in the translocation of signal peptide-containing precursor polypeptides across the ER membrane. 23 The Sec61 complex forms the central apparatus of the ER membrane protein translocation machinery, enabling proteins to be translocated into the ER lumen or integrated into the ER membrane. During co-translational translocation, the Sec61 complex functions in coordination with the signal recognition particle (SRP), SRP receptor, and ribosome to deliver nascent polypeptide chains into the ER lumen. 24 Within this process, SEC61G stabilizes the conformation of SEC61A, thereby maintaining efficient ribosome–channel docking and proper channel gating dynamics, both of which are critical for effective translocation. 25 In addition, the Sec61 channel cooperates with the translocating chain-associated membrane protein TRAM1 to facilitate the insertion of nascent proteins into the ER. 25-27 SEC61G also plays a critical role in membrane protein biogenesis. The Sec61 channel facilitates the insertion of transmembrane proteins into the ER membrane by mediating the insertion of transmembrane segments, whereas the insertion of subsequent segments is transferred to the multi-pass translocon complex. 6 , 28 , 29 Furthermore, the Sec61 complex participates in the biosynthesis and membrane insertion of tail-anchored proteins into the ER. 30-32 Extended function: passive ER calcium leak channel Beyond its role in protein translocation, the Sec61 complex has been identified as a major pathway for passive Ca²⁺ leakage from the ER, thereby contributing to intracellular calcium homeostasis. In addition to its roles in ribosome binding, membrane protein insertion, and nascent polypeptide translocation, the Sec61 channel functions as a passive ER calcium leak channel. 6 By regulating the efflux of calcium from the ER lumen into the cytosol, the Sec61 complex plays a central role in maintaining cellular calcium balance. The dysfunction of this atypical ER Ca²⁺ leak channel is associated with multiple pathophysiological conditions, including ER stress, apoptosis, ischemia–reperfusion injury, type 2 diabetes, and cancer. 9 , 10 Notably, the Sec61 channel is subject to dynamic regulation between its dual functional states: protein translocation and calcium leakage. Binding immunoglobulin protein, an ER luminal chaperone, can limit calcium leakage by interacting with a specific luminal loop of the Sec61α subunit. 8 The transition between open and closed conformations is tightly controlled by multiple factors, including nascent polypeptides on the cytosolic side and molecular chaperones such as binding immunoglobulin protein on the luminal side. Disruption of the balance between protein translocation and Ca²⁺ leakage has been implicated in the pathogenesis of a group of disorders, collectively termed “Sec61 channelopathies”. 33 In summary, as an integral component of the Sec61 heterotrimer, SEC61G contributes to channel assembly and conformational stabilization, ensuring efficient translocation of nascent polypeptides into the ER lumen as well as proper regulation of ER Ca²⁺ leakage. These functions collectively maintain the balance between proteostasis and calcium homeostasis. The classical physiological roles of SEC61G provide an essential framework for understanding its dysregulation and oncogenic functions in cancer. Bioinformatics analysis Pan‑cancer CRISPR‑Cas9 dependency analysis Data were obtained from the Sanger CRISPR Project Score database (https://depmap.org/portal/data_page/). Raw read counts were processed using the Achilles pipeline. Only cell lines marked as passing both quality control (QC) steps in Supplementary Table of the Project Score release and with complete copy number data were retained. The final analysis included 831 cancer cell lines across 31 tumor types. Gene dependency was quantified using CERES scores, which correct for copy‑number effects. A CERES score of 0 indicates no dependency (gene knockout does not impair proliferation), while more negative scores indicate stronger dependency (the gene is more essential for cell growth). A score of −1 approximates the median score of known pan‑essential genes. CERES scores for SEC61G were extracted from the CRISPRGeneDependency.csv file and merged with cell line annotations (cancer type, lineage) from the Model.csv file using the ModelID as the key. Visualization was performed using R version 4.3.2 with the ggplot2, dplyr, forcats, and patchwork packages. TCGA subtype‑specific Kaplan‑Meier survival analysis Gene expression and clinical data were downloaded from the UCSC Xena data hub (https://xena.ucsc.edu; Goldman et al., 2020). HTSeq‑FPKM expression profiles and overall survival (OS) information for 33 cancer types were obtained from TCGA. Only tumor samples were included; normal tissues and samples with missing survival data were excluded. Raw FPKM values were converted to TPM (Transcripts Per Million) and then log₂‑transformed (log₂(TPM+1)) to stabilize variance. Within each cancer subtype, patients were dichotomized into high‑ and low‑SEC61G expression groups using the median expression level as the cutoff. Survival analyzes were performed using R version 4.3.2 with the survival and survminer packages. Kaplan‑Meier curves were generated, and differences between groups were assessed by the two‑sided log‑rank test. Univariate Cox proportional hazards regression was used to estimate hazard ratios (HR) with 95% confidence intervals (CI). To control for multiple testing, the Benjamini‑Hochberg false discovery rate (FDR) correction was applied to the log‑rank p‑values across the 33 subtypes. Pan‑cancer expression analysis Gene expression data for SEC61G across multiple cancer types were obtained from The Cancer Genome Atlas (TCGA) and the Genotype‑Tissue Expression (GTEx) project via the UCSC Xena data hub. Tumor samples from TCGA and healthy normal tissue samples from GTEx were integrated to increase the normal control sample size, thereby improving the statistical power of differential expression analysis. The combined dataset was subjected to uniform batch correction and normalization. Within each cancer type, expression values were z‑score normalized (z = (x−μ)/σ), and samples with |z‑score| > 3 were excluded as outliers. Differential expression between tumor and normal tissues was assessed using the Wilcoxon rank‑sum test. Pan-cancer expression and functional essentiality landscape of SEC61G Pan-cancer expression patterns Our integrated analysis of TCGA tumor samples and GTEx normal tissues showed that SEC61G expression was significantly upregulated in 26 out of 30 cancer types (Figure 1). Pan‑cancer expression of SEC61G (TCGA>Ex). SEC61G expression (log₂(TPM+1)) is significantly higher in tumor tissues compared to normal tissues in 26 out of 30 cancer types. (Wilcoxon rank‑sum test, p < 0.05). In 2025, Ye et al. performed a pan-cancer analysis of SEC61G, with a particular focus on cervical squamous cell carcinoma and adenocarcinoma. They reported that SEC61G is highly expressed across multiple malignancies and that its expression is significantly associated with overall survival (OS). Receiver operating characteristic curve analysis further confirmed its diagnostic value. Moreover, SEC61G expression was significantly correlated with immune cell infiltration, suggesting a role in modulating the tumor immune microenvironment. 20 Pan-cancer dependency landscape In addition to expression levels, gene essentiality represents a critical parameter for assessing therapeutic target potential. Using CRISPR–Cas9 genome-wide knockout screening data from the Dependency Map database, the functional essentiality of SEC61G was analyzed across 31 tumor types and 831 cancer cell lines. 34 , 35 Gene dependency was quantified using the CERES score, where more negative values indicate greater cellular dependence on the gene. 36 At the individual cell line level, the breast cancer cell line SUM159PT exhibited the strongest dependence on SEC61G (CERES score = −1.496). At the tumor type level, cervical squamous cell carcinoma and adenocarcinoma showed the lowest average CERES score (−1.107 across 12 cell lines), indicating the highest overall dependency. Strong dependency was also observed in mesothelioma (−1.097), acute lymphoblastic leukemia (−1.095), and multiple myeloma (−1.069). Additional tumor types, including ovarian cancer (−1.054), liver HCC (−1.066), and NSCLC (−1.019), also exhibited substantial dependence on SEC61G (Figure 2A-B and Supplementary Tables S1 and 2). Notably, the dependency profile of SEC61G partially overlaps with its expression pattern. In cervical cancer, SEC61G demonstrates both high expression and strong functional dependency, indicating that it possesses the dual characteristics of high expression and high essentiality, which may render it a particularly promising therapeutic target. Similar concordance between expression and dependency is observed in ovarian cancer, HCC, and NSCLC. In contrast, other cancer types, such as thyroid cancer and CRC, exhibit elevated SEC61G expression but only moderate dependency, suggesting the presence of tumor-specific regulatory mechanisms or compensatory pathways. SEC61G dependency landscape. (A) Top 200 SEC61G‑dependent cell lines ranked by CERES score (left = most dependent). Colors indicate cancer type. SUM159PT is highlighted. Dashed line: LOESS smooth. (B) Mean CERES score (±SD) per cancer type (≥3 cell lines), ordered from most to least dependent (top to bottom). Red: key cancer types (CESC, MESO, ALL, MM, OV, LIHC, NSCLC). Point size = number of cell lines. Dotted line: CERES = −1 (pan‑essential median). Prognostic value across cancers High SEC61G expression is consistently associated with poor clinical outcomes across multiple malignancies and has been identified as an independent prognostic factor in several cancer types (Table 1). Table 1.Pan-cancer prognostic association of SEC61G.Cancer typesAuthorsPMIDKey conclusionsHNSCCLu T, et al. and Shi Y, et al.3459079234173014SEC61G is highly expressed in HNSCC and is an independent prognostic factor for OS (HR = 1.80, P < 0.001).LUADZheng Q, et al.34774014High SEC61G expression is an independent prognostic factor in LUAD (HR = 1.760, P < 0.001).GBMLiu B, et al.31094363High SEC61G expression predicts poor prognosis and poor response to TMZ and radiotherapy.HCCGao H, et al.33171060SEC61G mRNA levels significantly correlate with survival time in HCC patients.HCCLiu Y, et al.PPR678217 (PPR) Preprint, not peer-reviewedCo-high expression of SSR3 and SEC61G is associated with shorter OS in HCC (P < 0.01).CESCYe Y, et al.41212448High SEC61G expression significantly correlates with OS in cervical squamous cell carcinoma and adenocarcinoma.CESCFan Y, et al.36092956High SEC61G expression predicts poor prognosis, and knockdown inhibits proliferation.CRCHiguchi S, et al.40413702SEC61G is upregulated in CRC and is associated with poor prognosis.BCMa J, et al.34039955High SEC61G expression predicts poor prognosis.OSCCZhang S, et al.37893092High SEC61G expression predicts poor prognosis. Pan-cancer prognostic association of SEC61G. In HNSCC, Lu et al. demonstrated, using TCGA-HNSCC and GSE65858 datasets, that SEC61G is highly expressed in HNSCC and negatively associated with OS (TCGA: p < 0.001; GSE65858: p = 0.019). Multivariate analysis confirmed SEC61G as an independent prognostic factor (HR = 1.80, 95% CI: 1.35–2.39, p < 0.001). 16 These findings were independently validated by Shi et al., who also reported a significant association between high SEC61G expression and poor survival in HNSCC. 37 In lung adenocarcinoma, Zheng et al. reported that elevated SEC61G expression is significantly associated with poor prognosis. Multivariate analysis identified SEC61G as an independent prognostic factor in TCGA cohort (HR = 1.760, 95% CI: 1.297–2.388, p < 0.001). Furthermore, hypomethylation of the SEC61G promoter was correlated with worse OS (p = 0.0014). 38 In GBM, Liu et al. conducted a systematic evaluation using TCGA and Chinese Glioma Genome Atlas databases and confirmed SEC61G as an independent prognostic factor. High expression was also associated with poor outcomes following TMZ treatment and radiotherapy. 12 In HCC, Gao et al. demonstrated that SEC61G mRNA expression is significantly correlated with patient survival based on TCGA data. 15 Moreover, preliminary data from a preprint (Liu et al., PPR678217; not peer-reviewed) suggest that co‑overexpression of SSR3 and SEC61G may be associated with shorter OS (p < 0.01) and more advanced clinical stage (p < 0.05) in HCC. (https://europepmc.org/article/PPR/PPR678217). In cervical cancer, Ye et al. reported that elevated SEC61G expression is significantly correlated with OS in cervical squamous cell carcinoma and adenocarcinoma, with receiver operating characteristic curve analysis yielding an area under the curve of 0.807, indicating good diagnostic performance. 20 Fan et al. further demonstrated that SEC61G overexpression predicts poor prognosis and that its knockdown inhibits cervical cancer cell proliferation. 39 In CRC, Higuchi et al. reported that SEC61G expression is significantly upregulated in tumor tissues and associated with poor patient prognosis. 19 In breast cancer, Ma et al. demonstrated that high SEC61G expression predicts poor prognosis in both TCGA-BRCA dataset and an independent breast cancer cohort from Nanjing Medical University. 17 Jin et al. further showed that SEC61G expression is associated with epithelial–mesenchymal transition (EMT), immune infiltration, and patient survival in breast cancer, indicating its potential value as both a diagnostic and prognostic biomarker. 40 In renal cancer, Meng et al. found that SEC61G expression is upregulated in tumor tissues and is associated with poor prognosis. 41 In oral squamous cell carcinoma, Zhang et al. reported that patients in the low SEC61G expression group exhibited significantly higher OS than those in the high SEC61G expression group (p < 0.05), and SEC61G expression was identified an independent prognostic predictor. 42 In other malignancies, patients with metastatic urothelial carcinoma exhibiting high SEC61G expression derived less benefit from atezolizumab treatment in terms of OS (p = 0.006). 16 To further evaluate the cancer-type specificity of the prognostic value of SEC61G, we analyzed tumor subtypes within TCGA database. Five subtypes showed statistically significant HR > 1, suggesting that high SEC61G expression is associated with poor prognosis. Specifically, in cervical squamous cell carcinoma (CESC_CSCC), elevated SEC61G expression was significantly associated with shorter OS, consistent with the prognostic trend reported by Ye et al. in the overall cervical cancer cohort. 20 In low-grade glioma, all three subtypes—astrocytoma (LGG_Astro), oligodendroglioma (LGG_Oligo), and mixed oligoastrocytoma (LGG_OligoAstro)—showed a significant association between high SEC61G expression and poor prognosis. Leiomyosarcoma (SARC_LMS) also exhibited a positive correlation between high SEC61G expression and adverse prognosis (Figure 3). Forest plot of TCGA subtype-specific prognostic analysis for SEC61G. Hazard ratios (HR) with 95% confidence intervals (CI) are shown for cancer subtypes in which high SEC61G expression was significantly associated with shorter overall survival (HR > 1, P < 0.05). Data were normalized to TPM and log₂(TPM+1) transformed. Multiple testing was corrected by Benjamini-Hochberg FDR, and only subtypes with FDR < 0.05 are shown. Oncogenic mechanisms of SEC61G in specific cancer types The pan-cancer analyzes described above establish a broad association between high SEC61G expression and poor prognosis. However, the molecular mechanisms through which SEC61G exerts its oncogenic functions substantially differ among cancer types. Overall, these mechanisms can be classified into three major categories: (1) immune regulation dependent on its canonical protein translocation function, as exemplified by SEC61G-mediated ER translocation and membrane localization of immune checkpoint ligands in GBM; (2) calcium signaling regulation derived from the calcium leak function of the Sec61 channel, as exemplified by SEC61G overexpression enhancing ER calcium leakage and activating EGFR signaling via calmodulin in CRC; and (3) non-canonical mechanisms independent of classical Sec61 channel activity, such as SEC61G-mediated antagonism of UBE3C-dependent ubiquitination and degradation of phosphoglycerate mutase 1 (PGAM1), thereby promoting glycolytic reprogramming in NSCLC. These mechanisms are discussed below by cancer type and summarized in Table 2. Table 2.Mechanisms of SEC61G action.Cancer typesExpression characteristicsCore functions and mechanismsClinical significancesRepresentative referencesNSCLCBoth mRNA and protein levels are upregulatedAntagonizes UBE3C to stabilize PGAM1 and enhance glycolysis; promotes microglial M2 polarization; inhibits M1 polarization; impairs TLS maturationPredictive biomarker for brain metastasis risk; potential therapeutic target39990664GBMCo-amplified with EGFR (>70%); overexpressed in 77% of cases. Both mRNA and protein levels are upregulatedPromotes ER translocation, glycosylation, and membrane localization of ICLs such as PD-L1, PVR, and PD-L2; mediates immune evasionPrognostic biomarker; combination therapeutic target with EGFR-TKI3752355631094363CRCMarkedly upregulated in tumor tissues (mRNA and protein levels confirmed)Elevates cytosolic Ca²⁺ and activates EGFR signaling via CaM to promote G1/S phase transitionPrognostic biomarker; potential therapeutic target40413702HCCBoth mRNA and protein levels are upregulatedPromotes proliferation, migration, and invasion, and inhibits apoptosis; synergizes with SSR3 to promote proliferationPotential therapeutic target; target for miRNA-based therapy33171060PPR678217HNSCCOverexpression driven by DNA amplification (9.66%); Both mRNA and protein levels are upregulatedSuppresses infiltration of B cells, CD4⁺/CD8⁺ T cells, macrophages, neutrophils, and dendritic cellsIndependent prognostic factor; negative predictive biomarker for immunotherapy3459079234173014OSCCHighly expressed in tumor tissues (mRNA and protein levels confirmed)UnknownIndependent prognostic predictor; diagnostic and prognostic biomarker37893092CESCHighly expressed in tumor tissues (mRNA and protein levels confirmed)Activates the MAPK pathway to promote proliferationDiagnostic and prognostic biomarker4121244836092956BCHighly expressed in TCGA cohortsTranscriptionally regulated by E2F1; promotes progression via glycolysis and EMTIndependent risk factor34039955Renal cancerUpregulated in tumor tissuesKnockdown inhibits proliferation, migration, and invasion, and promotes caspase-dependent apoptosisPrognostic biomarker; therapeutic target33846795OVUpregulated in chemotherapy-resistant settingsDNA damage inhibits SEC61G mRNA degradation via the BRCA1-PARP13 axis; ER calcium leakage activates Akt pro-survival signalingMechanism of chemotherapy resistance41052987 Mechanisms of SEC61G action. NSCLC: dual metabolic and immune drivers of brain metastasis Brain metastasis is a leading cause of death in patients with NSCLC. 43 In 2025, Zhou et al. reported, for the first time, a critical role of SEC61G in NSCLC brain metastasis. 18 They found that SEC61G expression is significantly upregulated in brain metastatic lesions. Mechanistically, SEC61G stabilizes PGAM1 and enhances glycolytic activity by competitively inhibiting the E3 ubiquitin ligase UBE3C, thereby preventing PGAM1 ubiquitination and degradation. This process provides metabolic support for tumor cell colonization within the brain microenvironment. The precise molecular basis by which SEC61G, an ER membrane protein, interferes with the cytosolic UBE3C–PGAM1 interaction remains to be fully elucidated, and may involve an as-yet-unidentified bridging factor or post‑translational processing of SEC61G. Concurrently, SEC61G promotes microglial polarization toward the M2 phenotype while suppressing M1 polarization, impairs maturation of tertiary lymphoid structures (TLSs), and remodels the local immunosuppressive microenvironment. Several non‑mutually exclusive hypotheses merit consideration. First, SEC61G might undergo regulated intramembrane proteolysis or alternative splicing to release a cytosolic fragment capable of antagonizing UBE3C directly or indirectly. Second, SEC61G could nucleate a membrane‑proximal signaling platform that sequesters UBE3C or its obligate cofactors at the ER surface, thereby limiting PGAM1 ubiquitination in a spatially restricted manner. Third, SEC61G overexpression may indirectly modulate the cellular redox state or calcium homeostasis in ways that post‑translationally alter UBE3C activity. Systematic mapping of the SEC61G interactome and identification of potential SEC61G cleavage products in NSCLC models will be required to distinguish among these possibilities. GBM: EGFR co-amplification and immune evasion In 2023, Zeng et al. demonstrated the key role for SEC61G in immune evasion in EGFR-amplified GBM. 44 SEC61G is frequently co-amplified with EGFR at chromosome 7p11.2. It promotes the ER translocation, glycosylation, and membrane localization of immune checkpoint ligands, including PD-L1, PVR, and PD-L2, enabling tumor cells to evade CD8⁺ T-cell-mediated immune surveillance. SEC61G depletion significantly increased CD8⁺ T-cell infiltration and anti-tumor immune activity. Moreover, SEC61G inhibition enhanced the efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in animal models, suggesting a potential combination strategy for EGFR-amplified GBM. CRC: a calcium signaling-mediated mechanism In 2025, Higuchi et al. revealed a mechanism by which SEC61G promotes CRC progression through enhanced ER calcium leakage. 19 SEC61G overexpression significantly increased cytosolic Ca²⁺ levels, thereby activating EGFR signaling through calmodulin and promoting cell cycle progression from G1 to S phase, ultimately enhancing CRC cell proliferation. Single-cell RNA-seq and spatial transcriptomics further revealed that SEC61G is highly expressed in tumor epithelial cells and co-expressed with EGFR pathway-related genes. Because the Sec61 channel itself functions as a passive ER Ca²⁺ leakage pathway, upregulation of SEC61G expression exacerbates calcium leakage as an oncogenic extension of its physiological role in tumors. This finding expands the mechanistic spectrum of SEC61G from protein translocation-dependent immune regulation to signal activation driven by calcium homeostasis dysregulation. HCC In HCC, Gao et al. showed in 2020 that SEC61G knockdown inhibits cell proliferation, induces apoptosis, and suppresses migration and invasion. 15 In 2026, they further reported a therapeutic strategy involving engineered exosomes to deliver miR-488-3p targeting SEC61G, which significantly inhibited HCC cell proliferation, migration, and invasion in vitro. 45 In addition, co-expression of SSR3 and SEC61G synergistically promoted HCC cell proliferation, and concurrent high expression of both genes was associated with shorter OS (PPR678217). Other cancer types In cervical cancer, Ye et al. reported that SEC61G promotes the proliferation of cervical squamous cell carcinoma and adenocarcinoma through activation of the MAPK signaling pathway. 39 In breast cancer, Ma et al. found that the transcription factor E2F1 directly binds to the SEC61G promoter and regulates its expression, thereby promoting tumor progression and metastasis through glycolysis and EMT. 17 In renal cancer, Meng et al. confirmed that SEC61G expression is upregulated in tumor tissues and is associated with poor prognosis; its knockdown inhibited proliferation, migration, and invasion while promoting apoptosis. 41 In ovarian cancer, Sun et al. revealed that DNA damage inhibits SEC61G mRNA degradation via the BRCA1–PARP13 axis. The resulting upregulation of SEC61G expression was observed to subsequently induce ER calcium leakage and activate the Akt pro-survival pathway, thereby linking SEC61G to the DNA damage response and chemotherapy resistance in ovarian cancer for the first time. 46 Altogether, the oncogenic functions of SEC61G exhibit strong cancer-context dependency. In EGFR-highly amplified GBM, SEC61G primarily contributes to translocation-dependent processing of immune ligands, whereas in the metabolically stressed microenvironment of brain metastases, it preferentially drives non-canonical glycolytic reprogramming. This functional plasticity suggests that the interactome or post-translational modifications of SEC61G substantially differ among cancer types, warranting further investigation (Figure 4). Diverse oncogenic mechanisms of SEC61G across cancer types. SEC61G drives malignant progression through both classical protein translocation functions and non-canonical regulatory mechanisms. In NSCLC, SEC61G enhances glycolysis via the UBE3C-PGAM1 axis and promotes microglial M2 polarization, thereby facilitating brain metastasis. In GBM, SEC61G is co-amplified with EGFR and stabilizes PD-L1 and PVR to mediate immune evasion. In CRC, SEC61G elevates cytosolic Ca²⁺ levels to activate the EGFR pathway. In HCC, SEC61G promotes proliferation and migration and modulates chemosensitivity. In breast cancer, cervical cancer, renal cancer, and ovarian cancer, SEC61G contributes to malignant progression through E2F1-mediated transcriptional regulation, MAPK pathway activation, inhibition of apoptosis, and BRCA1-PARP13 axis-mediated ER calcium leakage, respectively. Therapeutic response and clinical translation of SEC61G Regulation of chemotherapy sensitivity 1. Cisplatin and Cancer Stem Cell Traits in HNSCC Cisplatin and Cancer Stem Cell Traits in HNSCC In addition to its association with etoposide and platinum resistance, SEC61G plays a critical role in the acquisition of cisplatin-induced cancer stem cell traits. In HNSCC, low-dose cisplatin treatment induces SEC61G expression. 47 SEC61G knockdown significantly attenuates cisplatin-induced ER calcium leakage and phosphorylation of ERK1/2 and AMPK, thereby suppressing cisplatin-induced autophagy. 47 Mechanistic studies further showed that SEC61G enhances cisplatin-induced cancer stem cell marker expression, sphere formation, and invasion capability by promoting Ca²⁺-mediated autophagy. 47 These effects are reversible upon treatment with the autophagy inhibitor chloroquine. These findings identify a previously unrecognized role of SEC61G in chemotherapy-induced cancer stem cell phenotypes and suggest that targeting SEC61G can help prevent recurrence driven by enhanced tumor stemness following chemotherapy. 47 2. TPF Chemotherapy in Hypopharyngeal Squamous Cell Carcinoma TPF Chemotherapy in Hypopharyngeal Squamous Cell Carcinoma In hypopharyngeal squamous cell carcinoma, Li et al. compared the gene expression profiles of patients who were sensitive or resistant to TPF chemotherapy using RNA-seq and found that SEC61G expression is significantly upregulated in the sensitive group. Its expression correlated with activation of glycolytic pathways and exhibited a significant negative correlation with CD8⁺ T-cell abundance. SEC61G is regulated by E2F1 and participates in antigen degradation through ubiquitin-dependent proteolytic pathways. In patient-derived xenograft models, the CDK4/6 inhibitor palbociclib combined with cetuximab significantly suppressed E2F1 and SEC61G expression while simultaneously activating MHC-I, thereby reducing tumor burden. SEC61G was thus identified as a central node linking chemotherapy sensitivity, metabolic reprogramming, and immune evasion. Targeting the E2F1–SEC61G axis may therefore enhance chemotherapy responsiveness and anti-tumor immunity. 48 Response to radiotherapy and targeted therapy 1. Radiotherapy and TMZ Resistance Mechanisms Radiotherapy and TMZ Resistance Mechanisms In GBM, Liu et al. not only reported an association between high SEC61G expression and poor prognosis following radiotherapy and TMZ treatment but also identified a significant correlation between SEC61G expression and Notch signaling through gene set enrichment and gene set variation analyzes, suggesting that SEC61G contributes to TMZ resistance through the Notch pathway. 12 Previous studies have found that Notch signaling plays a vital role in maintaining GBM stemness and TMZ resistance. The association between SEC61G and this pathway therefore provides important clues to the molecular mechanisms underlying SEC61G-mediated therapeutic resistance. 12 2. Combination Strategies Involving EGFR-TKIs Combination Strategies Involving EGFR-TKIs In the context of targeted therapy, Zeng et al. demonstrated that SEC61G, as a core subunit of the Sec61 translocon complex, promotes ER translocation, glycosylation, and membrane localization of immune checkpoint ligands, including PD-L1, PVR, and PD-L2, thereby enabling tumor cells to evade CD8⁺ T-cell-mediated immune surveillance. SEC61G inhibition significantly enhanced CD8⁺ T-cell infiltration and cytolytic activity. Moreover, the Sec61 inhibitor eeyarestatin I, when combined with EGFR-TKIs, effectively suppressed tumor growth and prolonged survival in GBM mouse models. 44 Immunotherapy response prediction 1. PD-L1 Expression Regulation PD-L1 Expression Regulation The role of SEC61G in regulating immune checkpoint molecules is not confined to GBM. In NSCLC, SEC61G knockdown significantly reduced PD-L1 expression, further supporting its cross-cancer role in immune checkpoint regulation. In lung adenocarcinoma, Zhou et al. showed through integrative analysis that SEC61G expression is positively correlated with glycolytic activity, EMT, and immunosuppressive phenotype, highlighting its potential value as a predictive biomarker for immunotherapy response. 49 2. TLS Impairment and Immune Microenvironment Remodeling TLS Impairment and Immune Microenvironment Remodeling In their study of NSCLC brain metastasis, Zhou et al. further clarified the mechanisms by which SEC61G shapes the immunosuppressive microenvironment. They found that SEC61G not only enhances glycolysis through the UBE3C–PGAM1 axis but also promotes microglial polarization toward the M2 phenotype while suppressing M1 polarization, accompanied by increased secretion of IL-6 and IL-10. Immune profiling revealed a negative gradient between SEC61G expression and the maturation status of TLSs: SEC61G expression was the highest in TLS-absent samples, intermediate in samples with immature TLSs, and lowest in samples with mature TLSs. As TLSs are crucial sites for adaptive anti-tumor immune responses, impairment of TLS maturation by SEC61G may further weaken immune surveillance and reduce immunotherapy efficacy. 18 3. SEC61G as a Predictive Biomarker of Immunotherapy Efficacy SEC61G as a Predictive Biomarker of Immunotherapy Efficacy The significance of SEC61G in predicting immunotherapy efficacy has been supported by multiple studies. In HNSCC, patients with high SEC61G expression exhibited significantly worse OS following atezolizumab treatment, suggesting that SEC61G serves as a negative predictive biomarker for immunotherapy. 16 In cervical cancer, Ye et al. revealed that SEC61G expression is significantly associated with immune cell infiltration and influences the tumor microenvironment by regulating ER stress response and immune infiltration. Collectively, these findings indicate that high SEC61G expression is closely linked to the establishment of an immunosuppressive microenvironment and that patients with elevated SEC61G expression may poorly respond to immune checkpoint inhibitor therapy. In summary, SEC61G exhibits marked functional plasticity in resistance to chemotherapy, radiotherapy, and immunotherapy. It activates autophagy-dependent stemness programs under cisplatin pressure, engages Notch signaling and immune ligand translocation under targeted therapy pressure, and remodels the tumor microenvironment under immune pressure. This stress-responsive functional switching positions SEC61G as a potential broad-spectrum sensitization target across treatment modalities (Figure 5). Regulatory network of SEC61G in therapeutic response and clinical translation. The diagram shows a central SEC61G protein embedded in the endoplasmic reticulum membrane. Four color‑coded modules are arranged around it. (Top left, blue) Chemotherapy: in HNSCC, cisplatin upregulates SEC61G, which promotes cancer stem cell (CSC) traits via Ca²⁺‑mediated autophagy; in hypopharyngeal squamous cell carcinoma, the E2F1‑SEC61G axis enhances glycolysis and reduces MHC‑I expression, affecting TPF chemotherapy response. (Top right, green) Radiotherapy and targeted therapy: in GBM, SEC61G activates the Notch pathway, contributing to temozolomide and radiotherapy resistance; SEC61G also facilitates ER translocation of PD‑L1 and PVR, enabling immune evasion, and its inhibition synergizes with EGFR‑TKIs. (Bottom left, orange) Immunotherapy prediction: in NSCLC, SEC61G knockdown reduces PD‑L1 expression; high SEC61G levels impair tertiary lymphoid structure (TLS) maturation and promote microglial M2 polarization, leading to an immunosuppressive microenvironment. (Bottom right, purple) Clinical translation: high SEC61G expression predicts poor response to atezolizumab (anti‑PD‑L1) in HNSCC and other cancers. Targeting strategies and clinical progress 1. Development of Sec61 Small-Molecule Inhibitors: From Natural Products to KZR-261 Development of Sec61 Small-Molecule Inhibitors: From Natural Products to KZR-261 Early Sec61 inhibitors derived from natural products exhibited anti-tumor activity in preclinical studies but failed to achieve clinical translation because of severe toxicity resulting from indiscriminate inhibition of the Sec61 client proteome and poor pharmacokinetic properties. Apratoxin A directly binds the Sec61α subunit and inhibits ER translocation of all tested Sec61 client proteins with similar potency, indicating a lack of substrate selectivity. 50 Mycolactone similarly binds Sec61α with high affinity and broadly blocks the biosynthesis of secreted and transmembrane proteins. 51 The non-selective inhibitory properties of these natural products are considered a major structural basis for their severe toxicity. To overcome these limitations, Kezar Life Sciences developed a new generation of synthetic small-molecule inhibitors, KZR-834 and its clinical candidate KZR-261, through structural optimization. Lowe et al. reported that these compounds directly bind the Sec61 channel, selectively block ER translocation of pro-tumorigenic factors such as PD-1, IL-2, and HER3, and activate the unfolded protein response. Unlike natural product inhibitors, KZR-261 inhibits only approximately 2%–5% of Sec61 client proteins, primarily those enriched among secreted and type I/II transmembrane proteins. This property of “multi-target but non-pan-inhibition” is believed to underlie its relatively favorable tolerability. 21 Cryo-EM structural analysis revealed that KZR-261 forms a hydrogen bond network with residues Q127/N300 of Sec61α through its sulfonamide group, thereby stabilizing the closed conformation of the lateral gate. Its binding site is located in the central pore region formed by SEC61A rather than on the SEC61G subunit. Thus, KZR-261 acts as a selective inhibitor of the Sec61 channel, blocking only a small fraction (approximately 2‑5%) of its client proteins, and its anti-tumor effects stem from blockade of Sec61-mediated translocation rather than specific targeting of SEC61G. In clinical development, KZR-261 has demonstrated anti-tumor activity both as a monotherapy and in combination with anti-PD-1 immunotherapy across multiple in vivo models. Based on these preclinical data, KZR-261 has entered a first-in-human, open-label, multicenter phase I clinical trial (NCT05047536) for advanced solid malignancies. Preliminary results indicate that durable disease stabilization can be achieved at tolerated doses. The trial includes cohorts with melanoma/uveal melanoma, mesothelioma, CRC, and castration-resistant prostate cancer, as well as a pan-tumor cohort. 21 2. Safety and Target Specificity Dilemma Safety and Target Specificity Dilemma Despite encouraging preclinical data and preliminary clinical findings, major challenges remain regarding the safety and target specificity of KZR-261 as a Sec61 channel inhibitor. The Sec61 channel is a constitutively expressed and essential protein complex responsible for the biosynthesis of approximately one-third of the human proteome, and it plays an indispensable role in maintaining protein homeostasis in normal cells. Direct inhibition of this channel therefore carries an inherent risk of systemic toxicity, and the therapeutic window largely depends on whether tumor cells are substantially more dependent on protein translocation stress than normal cells. Although KZR-261 has been described as “well-tolerated” in preclinical models and having “minimal side effects” in normal cells, this represents an improvement relative to natural product inhibitors rather than a complete resolution of the safety problem. First-generation natural product inhibitors failed because of severe toxicity caused by indiscriminate inhibition. 50 , 52 Second-generation inhibitors reduced toxicity by narrowing the spectrum of inhibited client proteins but did not eliminate the broader consequences of perturbing Sec61 channel function. 22 In the phase I trial, the preliminary conclusion of “good tolerability” is based on short-term dosing and limited sample size. Long-term safety, particularly the possibility of cumulative toxicity in normal tissues with high secretory activity (e.g., pancreas, liver, and plasma cells), remains to be established through larger studies with longer follow-up. 21 It should also be emphasized that KZR-261 is not a SEC61G-specific inhibitor. Existing Sec61 small-molecule inhibitors bind the central pore formed by the Sec61α subunit, and their pharmacological effects are mediated by inhibition of the overall protein translocation function of the Sec61 channel. Therefore, equating the development of Sec61 channel inhibitors with specific targeting of SEC61G reflects a conceptual conflation at the target level. Likewise, eeyarestatin I binds the central pore formed by Sec61α and inhibits protein translocation by blocking transfer of nascent polypeptides to the Sec61 complex. 53 SEC61G contributes indirectly to translocation by stabilizing channel conformation, but it is not the direct pharmacological target of inhibitors such as eeyarestatin I. 3. miRNA Therapy and Biomarker Development miRNA Therapy and Biomarker Development In contrast to strategies targeting the entire Sec61 channel, approaches directed specifically at the SEC61G gene are also being explored. Gao et al. (2026) reported a preclinical proof‑of‑concept study using engineered exosomes to deliver miR-488-3p targeting SEC61G, which inhibited HCC cell proliferation, migration, and invasion in vitro. However, these findings are limited to cell‑based assays and require substantial in vivo validation before clinical translation. 45 Therefore, miRNA therapies still face substantial challenges related to delivery efficiency, off-target effects, and immunogenicity, and extensive validation is needed before clinical translation. In terms of biomarker development, Li et al. showed through single-cell sequencing analysis that SEC61G can serve as a risk indicator and biomarker for lung cancer brain metastasis (https://labs.sciety.org/articles/by?article_doi=10.21203/rs.3.rs-8332095/v1). Further, Zhang et al. reported that SEC61G can serve as a diagnostic and prognostic biomarker in oral squamous cell carcinoma. 42 Collectively, these studies highlight the multifaceted potential of SEC61G in precision oncology, although its value as a companion diagnostic biomarker still requires validation in prospective clinical cohorts. Considering the difficulty of circumventing physiological toxicity through direct inhibition of the Sec61α pore, together with the absence of a classical enzymatic active site in SEC61G, future intervention strategies may pivot toward the following approaches: 1) protein–protein interaction inhibitors designed to disrupt the interface between the SEC61G transmembrane helix and Sec61α and 2) proteolysis-targeting chimeras designed to exploit the cytosolic N-terminal sequence of SEC61G for selective degradation. Building on these considerations, we propose a forward‑looking research roadmap with two parallel trajectories. First, high‑resolution structural mapping of the SEC61G–SEC61A transmembrane interface is needed to identify druggable pockets for the rational design of protein–protein interaction inhibitors. Second, the cytosolic N‑terminus of SEC61G represents a tractable handle for the development of proteolysis‑targeting chimeras (PROTACs) or molecular glue degraders, enabling selective elimination of SEC61G without global channel blockade. Preclinical validation of these subunit‑specific strategies, coupled with systematic elucidation of the SEC61G interactome across cancer types, will determine whether SEC61G can transition from a compelling biomarker to a genuine therapeutic target (Figure 6). Forward-looking therapeutic strategies targeting SEC61G. Left: PPI inhibitor strategy disrupting the SEC61G–SEC61A interaction interface. Right: PROTAC degrader strategy recruiting an E3 ligase to the cytosolic N-terminus of SEC61G for ubiquitination and proteasomal degradation. Both strategies converge toward subunit-specific therapeutic targeting. Challenges and perspectives Distinguishing SEC61G‑specific effects from global Sec61 complex impairment A fundamental challenge in interpreting the oncogenic functions of SEC61G is that it is an essential structural subunit of the Sec61 heterotrimer. Knocking down SEC61G by siRNA or shRNA destabilizes the entire complex, leading to global impairment of Sec61‑mediated protein translocation. This effect may be indistinguishable from knockdown of SEC61A or SEC61B. Thus, many of the anti‑tumor phenotypes observed after SEC61G knockdown might simply reflect generalized Sec61 channel inhibition, not SEC61G‑specific functions. That said, some evidence points to non‑canonical, complex‑independent activities that would justify a subunit‑specific therapeutic strategy. The most compelling example is the UBE3C‑PGAM1‑glycolysis axis in NSCLC, where SEC61G antagonizes a cytosolic E3 ubiquitin ligase. This function cannot be explained by ER protein translocation and likely does not require an intact Sec61 complex. Other examples include E2F1‑mediated transcriptional regulation of SEC61G in breast cancer and the SEC61G‑EGFR gene fusion in ependymoma, both pointing to roles independent of the heterotrimer. In contrast, for cancer types with only correlative expression‑prognosis associations, it remains unclear whether SEC61G directly contributes or merely mirrors the essentiality of the Sec61 complex. To strengthen the rationale for SEC61G‑directed therapies, future studies should systematically compare knockdown effects of SEC61G versus SEC61A or SEC61B in the same model systems, and test whether the UBE3C‑PGAM1 interaction or other non‑canonical mechanisms are preserved under conditions that maintain Sec61 complex integrity. Until such data are available, we suggest focusing SEC61G‑specific strategies on cancer types where non‑canonical, complex‑independent evidence already exists while recognizing that in other contexts, direct pore‑directed Sec61 inhibitors may be equally or more appropriate. Therapeutic strategies: two categories with distinct challenges In summary, therapeutic strategies can be broadly divided into two categories with distinct challenges. Pore‑directed inhibitors target the Sec61 channel itself and must contend with the inherent toxicity of global translocation blockade. In contrast, subunit‑directed approaches that specifically target SEC61G face the difficulty of disrupting a non‑enzymatic, largely structural protein without a classical active site. For Sec61 small‑molecule inhibitors, the core dilemma lies in balancing anti‑tumor efficacy against systemic toxicity. Because the constitutive expression of the Sec61 channel makes complete elimination of toxicity unlikely, future optimization should focus on improving client protein selectivity, developing tumor-specific delivery systems, and exploring rational combination strategies based on synthetic lethality. Even with markedly improved selectivity, the constitutive dependence of professional secretory tissues on Sec61‑mediated translocation may impose a fundamental ceiling on the maximum tolerated dose of any pore‑targeting inhibitor. Tissues such as pancreatic acinar cells, plasma cells, and hepatocytes are likely to remain vulnerable to even partial channel blockade, thereby constraining the achievable therapeutic index in non‑oncogene‑addicted settings. 1,54,55 By contrast, strategies that directly target the SEC61G subunit itself, such as designing molecules that specifically bind the SEC61G transmembrane helix or disrupt its interaction with SEC61A, remain largely theoretical, and no clinical candidate compounds have yet been reported. Nevertheless, given the high expression and functional essentiality of SEC61G in various tumors, together with its pan-cancer value as a prognostic biomarker, this direction warrants greater attention in future medicinal chemistry research. In practical terms, realizing this roadmap will require atomic‑resolution structures of the SEC61G–SEC61A transmembrane interface to enable rational design of protein–protein interaction inhibitors, as well as chemical biology campaigns to develop PROTACs or molecular glues that engage the cytosolic N‑terminus of SEC61G. Success in these endeavors would not only validate SEC61G as a druggable target but also establish a paradigm for selectively perturbing individual subunits of essential multi‑protein complexes in cancer therapy. Limitations of TCGA‑based prognostic analyzes The prognostic associations presented in Figure 3 are derived from retrospective TCGA data, which are subject to inherent limitations, including cohort heterogeneity, potential confounding factors (e.g., treatment history, stage distribution), and lack of independent prospective validation. Therefore, these findings should be interpreted as hypothesis‑generating and warrant confirmation in well‑designed prospective cohorts. More broadly, we acknowledge that most functional evidence supporting SEC61G as an oncogenic driver is limited to a few cancer types. For most other cancers listed in Table 1, the evidence remains correlative. The confounding effect of EGFR co‑amplification on SEC61G expression and prognosis has not been systematically addressed, particularly in EGFR‑amplified tumors such as GBM and NSCLC. Moreover, the molecular mechanisms driving SEC61G overexpression across different cancers—whether gene amplification, transcriptional upregulation, or post‑transcriptional regulation—are incompletely defined, and this distinction is critical for therapeutic stratification. Most functional studies rely on siRNA/shRNA‑mediated knockdown, which achieves partial rather than complete loss of function; the implications of full genetic ablation have not been explored. Finally, despite consistent prognostic associations, no prospective cohort or clinical validation study has yet evaluated SEC61G as a predictive biomarker in any cancer type. These limitations highlight the need for further mechanistic, genetic, and clinical investigations. Conclusion SEC61G has evolved from an accessory ER protein into a molecule with emerging pan‑cancer oncogenic relevance. Robust mechanistic evidence supports its role as an oncogenic driver in glioblastoma, non‑small cell lung cancer, and colorectal cancer, where functional experiments have validated its contribution to immune evasion, metabolic reprogramming, and calcium signaling dysregulation. In other cancer types such as breast cancer, oral squamous cell carcinoma, and renal cancer, the current evidence is largely correlative and awaits independent mechanistic validation. Nonetheless, the high expression and dependency profiles across multiple malignancies, together with its prognostic and immunomodulatory significance, justify further investigation. Although clinical translation remains constrained by challenges related to selectivity, safety, and biomarker validation, continued advances in mechanistic research and therapeutic development may establish SEC61G as a promising target for precision diagnosis and treatment in selected cancer types. Supplementary Material Supplementary Table S2 Cancer type summary.docx Supplementary Table S1 Top cell lines.docx Supplementary Table S1 Top cell lines.docx Acknowledgments We would like to thank the DepMap Project, The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx) project, and other public databases for providing the data used in this study. All authors read and approved the final manuscript. Funding Statement This work was supported by National Natural Science Foundation of China (82160536). Disclosure statement No potential conflict of interest was reported by the author(s). Data availability statement Data sharing is not applicable to this article, as no new data were created or analyzed in this study. All data used in the original analyzes presented in this review are publicly available through the DepMap portal (depmap.org) and the TCGA Research Network (cancergenome.nih.gov). Ethics approval statement This study does not need ethical approval. Supplementary material Supplemental data for this article can be accessed at https://doi.org/10.1080/15384047.2026.2694136. Abbreviations AMP-activated protein kinase Breast Cancer Binding immunoglobulin Protein Breast Cancer susceptibility gene 1 Calmodulin Cyclin-Dependent Kinase 4/6 Computational correction of copy-number Effect in CRISPR-Cas9 Essentiality Screens Cervical Squamous Cell Carcinoma and Adenocarcinoma Cervical Squamous Cell Carcinoma (TCGA subtype) Chinese Glioma Genome Atlas Confidence Interval Colorectal Cancer Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated protein 9 Cryogenic Electron Microscopy Dependency Map E2F Transcription Factor 1 Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Epithelial–Mesenchymal Transition Endoplasmic Reticulum Extracellular signal-Regulated Kinase 1/2 Glioblastoma Gene Expression Omnibus Genotype-Tissue Expression Hepatocellular Carcinoma Human Epidermal growth factor Receptor 3 Head and Neck Squamous Cell Carcinoma Human Protein Atlas Hazard Ratio Immune Checkpoint Ligands Interleukin-2 Interleukin-6 Interleukin-10 small-molecule Sec61 inhibitor KZR-261 Low-Grade Glioma, Astrocytoma (TCGA subtype) Low-Grade Glioma, Oligodendroglioma (TCGA subtype) Low-Grade Glioma, Mixed Oligoastrocytoma (TCGA subtype) Long non-coding RNA Lung Adenocarcinoma Mitogen-Activated Protein Kinase Major Histocompatibility Complex class I microRNA messenger RNA Non-Small Cell Lung Cancer Overall Survival Oral Squamous Cell Carcinoma Ovarian Cancer Poly(ADP-Ribose) Polymerase family member 13 Programmed cell Death protein 1 Programmed Death-Ligand 1 Programmed Death-Ligand 2 Patient-Derived Xenograft Phosphoglycerate Mutase 1 Protein–Protein Interaction Proteolysis-Targeting Chimera Poliovirus Receptor RNA sequencing Sarcoma, Leiomyosarcoma (TCGA subtype) single-cell RNA sequencing Sec61 Translocon subunit Alpha Sec61 Translocon subunit Beta Sec61 Translocon subunit Gamma Signal Recognition Particle Signal Sequence Receptor subunit 3 The Cancer Genome Atlas Tertiary Lymphoid Structure Temozolomide Docetaxel, Cisplatin, and Fluorouracil (chemotherapy regimen) Translocating chain-Associated Membrane protein 1 Ubiquitin Protein Ligase E3C Unfolded Protein Response References Associated Data Supplementary Materials Supplementary Table S2 Cancer type summary.docx Supplementary Table S1 Top cell lines.docx Supplementary Table S1 Top cell lines.docx Data Availability Statement Data sharing is not applicable to this article, as no new data were created or analyzed in this study. All data used in the original analyzes presented in this review are publicly available through the DepMap portal (depmap.org) and the TCGA Research Network (cancergenome.nih.gov).